David Perol
Overview
Explore the profile of David Perol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
3649
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berdai D, Guerin A, Perol D, Girault C, Molimard M, Amiel P, et al.
Therapie
. 2024 Dec;
80(1):145-154.
PMID: 39710545
In line with the spirit of the Giens workshops, this article reports on the recommended evolution of the Ethics Committees (CPPs) and the Committees for Research Ethics (CER) in France....
2.
Berdai D, Guerin A, Perol D, Girault C, Molimard M, Amiel P, et al.
Therapie
. 2024 Nov;
80(1):135-144.
PMID: 39523125
No abstract available.
3.
Blay J, Chabaud S, Perol D, Cesne A
Lancet Oncol
. 2024 Oct;
25(11):e538.
PMID: 39481408
No abstract available.
4.
Antoine A, Perol D, Robain M, Bachelot T, Choquet R, Jacot W, et al.
Eur J Cancer
. 2024 Oct;
213:115072.
PMID: 39476445
Background: Demonstration of trial emulation ability to benchmark randomised controlled trials (RCTs) from real-world data (RWD) is required to increase confidence in the use of routinely collected data for decision...
5.
Blay J, Devin Q, Duffaud F, Toulmonde M, Firmin N, Collard O, et al.
Lancet Oncol
. 2024 Aug;
25(9):1163-1175.
PMID: 39127063
Background: The long-term impact of tyrosine kinase inhibitor (TKI) discontinuation on resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is unclear. We report the exploratory long-term outcomes...
6.
Blay J, Penel N, Toulmonde M, Valentin T, Chaigneau L, Rios M, et al.
Eur J Cancer
. 2024 Jul;
208:114228.
PMID: 39018632
Rationale: We report a phase II trial (OSAD93) testing CDDP with ifosfamide (IFO), without doxorubicin in neoadjuvant phase, in adult osteosarcoma with a 25 years follow-up. Patients And Methods: This...
7.
Verlingue L, Desevre M, Polito M, Garin G, Rodriguez C, Qing W, et al.
Acta Oncol
. 2024 May;
63:411-417.
PMID: 38807312
Background And Purpose: In this manuscript we describe the academic French multicentric molecular analysis platforms including PROFILER, promoted by Centre Léon Berard, and the multicentric personalized medicine trials MOST, MOST...
8.
Dufresne A, Attignon V, Ferrari A, Tonon L, Boyault S, Tabone-Eglinger S, et al.
Cancer Med
. 2024 Mar;
13(7):e7115.
PMID: 38553950
Introduction: The objective was to determine the added value of comprehensive molecular profile by whole-exome and RNA sequencing (WES/RNA-Seq) in advanced and refractory cancer patients who had no molecular-based treatment...
9.
Voisin A, Terret C, Schiffler C, Bidaux A, Vanacker H, Perrin-Niquet M, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2111-2120.
PMID: 38502104
Purpose: Xevinapant is an orally available inhibitor of apoptosis proteins (IAP) inhibitor. Preclinical data suggest that IAP antagonism may synergize with immune checkpoint blockers by modulating the NFκB pathway in...
10.
Untch M, Perol D, Mayer E, Cortes J, Nusch A, Cameron D, et al.
Eur J Cancer
. 2024 Mar;
202:113977.
PMID: 38460476
Background: Overall survival (OS) is a universally accepted measure of clinical benefit; however, prolonged follow-up is needed to observe sufficient events. Disease-free survival (DFS) has been widely adopted as a...